Second line chemotherapy in patients with castration-refractory prostate cancer. Ftom clinical studies to practice
Open Access
- 30 March 2019
- journal article
- research article
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 15 (1) , 84-91-91
Abstract
Prostate cancer (PC) is one of the most pressing problems of modern oncology due to high worldwide morbidity for this pathology. Annually, more than 1,100,000 new cases of PC are diagnosed worldwide. The main treatment method for patients with locally advanced and/or metastatic PC is hormone therapy. Androgen deprivation allows to achieve disease stabilization in more than 90 % of patients, but mean time to progression after hormone therapy in patients with metastatic PC is about 2 years. Patients with cancer progression and preserved castration level of testosterone transition to the stage of so-called castration-resistant prostate cancer (CRPC). Advanced CRPC not only has poor prognosis, it also significantly decreases quality of life of the patients. CRPC patient cohort is extremely heterogenous and included patients both with factors of favorable prognosis and fulminant course of the disease. Unfavorable prognostic factors for patients with metastatic CRCP are short response time for initial hormone therapy (12 months), presence of pain syndrome as well as presence of visceral metastases. Taxane chemotherapy remains one of the standard treatment methods in patients with metastatic CRPC and unfavorable prognostic factors.The article presents a review of studies dedicated to the effectiveness of various doses and regimens of 2nd line chemotherapy using cabazi-taxel in patients with metastatic CRPC as well as analysis of clinical cases of using this drug in real-life clinical practice.Keywords
This publication has 12 references indexed in Scilit:
- Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).Journal of Clinical Oncology, 2016
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor GrowthCancer Research, 2008
- Secondary Hormonal Therapy for Advanced Prostate CancerJournal of Urology, 2006
- Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling AxisJournal of Clinical Oncology, 2005
- Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate CancerClinical Cancer Research, 2005
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy ResistanceThe American Journal of Pathology, 2004
- Prostate Cancer: Screening, Diagnosis, and ManagementAnnals of Internal Medicine, 1993